本文已被：浏览 52次 下载 63次
投稿时间：2023-12-29 网络发布日期：2024-03-20
投稿时间：2023-12-29 网络发布日期：2024-03-20
中文摘要: 目的 探讨对2型糖尿病（T2DM）达格列净单药治疗和达格列净联合西格列汀治疗的疗效。方法 选取2022年1月至2023年12月期间南京市六合区中医院收治的62例T2DM患者作为研究对象，随机分为两组，每组31例。对照组仅接受达格列净（10 mg/d口服）治疗，而观察组同时接受达格列净（10 mg/d口服）和西格列汀治疗（100 mg/d口服）。两组均治疗3个月。对比两组治疗后血糖控制效果［空腹血糖（FPG）和糖化血红蛋白（HbA1c）］、血糖波动情况、炎症指标（C-反应蛋白）以及心脏功能（左心室射血分数）。结果 经过3个月治疗，与治疗前比较，两组治疗后FBG和HbA1c均明显下降（P<0.05）。与对照组比较，观察组患者FBG ［（6.96±0.87）mmol/L vs （7.91±0.96）mmol/L, t=4.083, P<0.01］和HbA1c ［（6.54±0.33）% vs（7.65±0.58）%， t=9.261, P<0.01］均明显下降，观察组的平均血糖标准差（SDBG）值和餐后血糖波动幅度更低（P<0.05），C反应蛋白更低和左心室射血分数更高（P<0.05）。结论 达格列净联合西格列汀在治疗2型糖尿病方面效果显著，能有效降低血糖水平，改善患者炎症反应和心脏功能。
Abstract:Objective To investigate the efficacy of single drug treatment of dapagliflozin and combination of dapagliflozin and sitagliptin in the treatment of type 2 diabetes mellitus (T2DM). Methods Sixty-two patients with T2DM admitted to Luhe District Hospital of Chinese Medicine from January 2022 to December 2023 were selected as research subjects, and the patients were randomly divided into two groups, with 31 cases in each group. The control group only received treatment with dapagliflozin (10 mg/d oral), while the observation group received both dapagliflozin (10 mg/d oral) and sitagliptin (100 mg/d oral) treatment. Both groups were treated for 3 months. The post-treatment blood glucose control effects ［fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c)］, blood glucose fluctuations, inflammatory markers ［C-reactive protein (CRP)］, and cardiac function ［left ventricular ejection fraction (LVEF)］ were compared between two groups. Results After 3 months of treatment, compared with before treatment, both groups showed a significant decrease in FPG and HbA1c after treatment (P＜0.05). Compared with the control group, FPG ［(6.96±0.87) mmol/L vs (7.91±0.96) mmol/L, t=4.083, P＜0.01］ and HbA1c ［(6.54±0.33)% vs (7.65±0.58)%, t=9.261, P＜0.01］ of patients in the observation group were significantly decreased, and the standard deviation of mean blood glucose (SDBG) and amplitude of postprandial blood glucose fluctuation (PPGE) were lower (P<0.05), CRP was lower and LVEF was higher (P<0.05) in the observation group compared to the control group. Conclusion Dapagliflozin combined with sitagliptin has a significant effect in the treatment of T2DM. It can effectively reduce the level of blood glucose, reduce the occurrence of hypoglycemia, and improve the inflammatory reaction and cardiac function of patients.
keywords: Dapagliflozin Sitagliptin Type 2 diabetes Fasting plasma glucose Glycated hemoglobin C-reactive protein Left ventricular ejection fraction Blood glucose fluctuations
文章编号： 中图分类号：R587.1 文献标志码：A
基金项目:南京市医疗机构中药传统制剂研究项目（NJCC-ZJ-202361）
| 作者 | 单位 |
| 陈辉 | 1. 江苏省中医院江北院区 南京市六合区中医院药学部，江苏 南京 211500 |
| 林跃松 | 1. 江苏省中医院江北院区 南京市六合区中医院药学部，江苏 南京 211500 |
| 裴琴 | 2. 江苏省中医院江北院区 南京市六合区中医院内分泌科，江苏 南京 211500； |
| 赵林钢 | 3. 南京中医药大学附属医院，江苏 南京 210029 |
引用文本：
陈辉,林跃松,裴琴,等.达格列净联合西格列汀治疗2型糖尿病的效果[J].中国临床研究,2024,37(3):401-404.
陈辉,林跃松,裴琴,等.达格列净联合西格列汀治疗2型糖尿病的效果[J].中国临床研究,2024,37(3):401-404.